Core Insights - Verona Pharma and Evolv Technologies are highlighted as strong investment opportunities with high momentum characteristics and Zacks Rank 1 (Strong Buy) [1][2][3] Company Summaries Verona Pharma (VRNA) - Focuses on developing innovative therapeutics for chronic respiratory diseases with significant unmet medical needs [1] - Zacks Consensus Estimate for current year earnings increased by 37.5% over the last 60 days [1] - Shares gained 69% over the last three months, outperforming the S&P 500's gain of 26% [2] - Possesses a Momentum Score of A [2] Evolv Technologies (EVLV) - Offers AI touchless screening technologies for weapons detection, identity verification, and health-related threats through Evolv Cortex AI(TM) software platform [2] - Zacks Consensus Estimate for current year earnings increased by 23.3% over the last 60 days [2] - Shares gained 100.7% over the last three months, significantly outperforming the S&P 500's gain of 25.9% [3] - Possesses a Momentum Score of B [3]